<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660008</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-15126</org_study_id>
    <nct_id>NCT02660008</nct_id>
  </id_info>
  <brief_title>Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon</brief_title>
  <official_title>A Randomized, Double-blind Trial of Single Doses of ZP4207 Administered s.c. to Hypoglycemic Type 1 Diabetic Patients to Describe the Pharmacokinetics and Pharmacodynamics of ZP4207 as Compared to Marketed Glucagon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a single-centre, randomized, double-blind, parallel trial in Group 1 and&#xD;
      cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic&#xD;
      Type 1 diabetic patients to evaluate the pharmacokinetics and pharmacodynamics of ZP4207 as&#xD;
      compared to marketed glucagon.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PD endpoint: Plasma glucose profiles 0-360 min above baseline (Area under the effect curve 0-360 min)</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD endpoint: Time to peak plasma glucose concentration (tmax)</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoint: Plasma ZP4207 and glucagon profiles 0-360 min</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoint: Peak plasma concentration (Cmax)</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK endpoint: Time to peak plasma concentration (tCmax)</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD endpoints: Percentage of patients achieving a plasma glucose concentration ≥70 mg/dL within 30 minutes after treatment</measure>
    <time_frame>During visit 2 and 3 (0-30min)</time_frame>
    <description>At visit 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints: Time to plasma glucose concentration of ≥70 mg/dL</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints: Percentage of patients achieving a plasma glucose increase of ≥20 mg/dL within 30 minutes after treatment</measure>
    <time_frame>During visit 2 and 3 (0-30min)</time_frame>
    <description>At visit 2 and 3,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints: Time to plasma glucose increase of ≥20 mg/dL</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK endpoints: Baseline adjusted glucagon profiles 0-360 min</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK endpoints: AUC0-inf for plasma ZP4207 concentration</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3, Area under the plasma curve from 0 to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: Insulin concentrations</measure>
    <time_frame>During visit 2 and 3 (0-360min)</time_frame>
    <description>At visit 2 and 3, insulin concentrations in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory endpoint: Changes in hypoglycaemic symptom scores from 0-30 minutes</measure>
    <time_frame>During visit 2 and 3 (0-30min)</time_frame>
    <description>At visit 2 and 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Number of participants with adverse events</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Changes or findings from baseline in physical examination</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>An examination of the following body systems will be performed:&#xD;
Head, ears, eyes, nose, throat (HEENT), incl. thyroid gland&#xD;
Heart, lung, chest&#xD;
Abdomen&#xD;
Skin and mucosae&#xD;
Musculoskeletal system&#xD;
Nervous system&#xD;
Lymph node&#xD;
Other findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Changes or findings from baseline (normal ranges) in clinical safety laboratory parameters</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>Haematology biochemistry, and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Changes or findings from baseline in vital signs</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>systolic/diastolic blood pressure (mmHg) and heart rate (beats per minute), body temperature (°C), respiratory frequency (RF/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Changes or findings from baseline in ECG</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>Heart rate, PQ, QRS, QT, QTcB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Local tolerability of injection site</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>Findings in local tolerability by means of the following assessments.&#xD;
spontaneous pain&#xD;
pain on palpation&#xD;
itching&#xD;
redness&#xD;
oedema&#xD;
induration/infiltration&#xD;
other</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability: Immunogenicity (Ant-Drug Antibody sampling)</measure>
    <time_frame>Through study completion (up to 63 days)</time_frame>
    <description>Antidrug antibodies incidences</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>ZP4207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GlucaGen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP4207</intervention_name>
    <description>Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients</description>
    <arm_group_label>ZP4207</arm_group_label>
    <other_name>analogue af human glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GlucaGen</intervention_name>
    <description>Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients</description>
    <arm_group_label>GlucaGen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained before any trial-related activities (trial-related&#xD;
             activities are any procedure that would not have been performed during normal&#xD;
             management of the patient).&#xD;
&#xD;
          2. Male and female patients with T1D for at least one year, as defined by the American&#xD;
             Diabetes Association.&#xD;
&#xD;
          3. Having been treated with insulin for T1D for at least 1 year.&#xD;
&#xD;
          4. Stable disease with HbA1c &lt; 8.5%.&#xD;
&#xD;
          5. Expected stable insulin treatment during participation in trial and 3 month prior to&#xD;
             the screening visit.&#xD;
&#xD;
          6. Age between 18 and 50 years, both inclusive.&#xD;
&#xD;
          7. Body weight between 60 and 90 kg, both inclusive.&#xD;
&#xD;
          8. Patients in good health according to age (medical history, physical examination, vital&#xD;
             signs, ECG, lab assessments), as judged by the Investigator.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously treated with ZP4207.&#xD;
&#xD;
          2. Known or suspected allergy to trial product(s) or related products.&#xD;
&#xD;
          3. Previous participation (randomization) in this trial.&#xD;
&#xD;
          4. Receipt of any investigational drug within 3 months prior to screening.&#xD;
&#xD;
          5. A history or presence of cancer, or any clinically significant cardiovascular,&#xD;
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,&#xD;
             hematological, dermatological, venereal, neurological, psychiatric diseases, or other&#xD;
             major diseases.&#xD;
&#xD;
          6. Clinically significant illness within 4 weeks before screening, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
          7. History of, or positive results to the screening test for Hepatitis B surface antigen&#xD;
             (HBsAg) or Hepatitis C antibodies&#xD;
&#xD;
          8. Positive result of test for HIV antibodies.&#xD;
&#xD;
          9. Any clinically significant abnormal hematology, biochemistry or urinalysis screening&#xD;
             tests, as judged by the Investigator.&#xD;
&#xD;
         10. Clinically significant abnormal ECG at screening as evaluated by the Investigator.&#xD;
&#xD;
         11. Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks&#xD;
             prior to screening.&#xD;
&#xD;
         12. A significant history of alcoholism or drug/chemical abuse, or who has a positive&#xD;
             result in the urine drug screen, or who consumes more than 14 units of alcohol per&#xD;
             week (one unit of alcohol equals about 250 mL of beer, 1 glass of wine, or 20 mL of&#xD;
             spirits).&#xD;
&#xD;
         13. Habitual smoking, i.e., daily smoking or more than 7 cigarettes/week within the last 3&#xD;
             months prior to screening. Patients have to accept refraining from smoking while at&#xD;
             the clinical site.&#xD;
&#xD;
         14. Patients with mental incapacity or language barriers which preclude adequate&#xD;
             understanding or cooperation, who are unwilling to participate in the trial, or who in&#xD;
             the opinion of the Investigator should not participate in the trial.&#xD;
&#xD;
         15. Surgery or trauma with significant blood loss within the last 2 months prior to&#xD;
             screening.&#xD;
&#xD;
         16. Any condition interfering with trial participation or evaluation or that could be&#xD;
             hazardous to the patient.&#xD;
&#xD;
         17. Severe hypoglycaemic events within one year prior to screening, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         18. Significant changes in basal insulin within 3 weeks before screening, as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         19. Clinically relevant diabetic complications (macrovascular disease with symptoms or&#xD;
             signs of coronary artery disease or peripheral vascular disease, microvascular disease&#xD;
             with symptoms or signs of neuropathy, gastroparesis, retinopathy, nephropathy, or poor&#xD;
             blood glucose control with polyuria, polydipsia, or weight loss), as judged by the&#xD;
             Investigator.&#xD;
&#xD;
         20. Females of childbearing potential who are pregnant, breast-feeding or intend to become&#xD;
             pregnant or are not using highly effective contraceptive methods (highly effective&#xD;
             contraceptive methods are considered those with a failure rate less than 1% undesired&#xD;
             pregnancies per year including surgical sterilisation, hormonal intrauterine devices&#xD;
             (coil), oral hormonal contraceptives, sexual abstinence or a surgically sterilised&#xD;
             partner) or postmenopausal women being amenorrheic for less than 1 year with serum FSH&#xD;
             level &lt;= 40 IU/L and not using highly effective contraceptive methods during the trial&#xD;
             and until one month after completion of the trial.&#xD;
&#xD;
         21. Male who is sexually active and not surgically sterilized who or whose partner(s) is&#xD;
             not using highly effective contraceptive methods (highly effective contraceptive&#xD;
             measures include surgical sterilisation, hormonal intrauterine devices [coil], oral&#xD;
             hormonal contraceptives, each in combination with spermicide-coated condoms), or who&#xD;
             is not willing to refrain from sexual intercourse from the first dosing until one&#xD;
             month after last dosing in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrike Hövelmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>January 6, 2016</study_first_submitted>
  <study_first_submitted_qc>January 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

